Cadence Pharmaceuticals (NASDAQ: CADX) and Cambrex Corporation (NYSE:CBM) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Insider & Institutional Ownership

98.3% of Cambrex Corporation shares are held by institutional investors. 2.5% of Cambrex Corporation shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Cadence Pharmaceuticals and Cambrex Corporation’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Cadence Pharmaceuticals N/A N/A N/A N/A N/A
Cambrex Corporation $515.45 million 3.56 $167.23 million $2.76 20.29

Cambrex Corporation has higher revenue and earnings than Cadence Pharmaceuticals.


This table compares Cadence Pharmaceuticals and Cambrex Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cadence Pharmaceuticals N/A N/A N/A
Cambrex Corporation 17.70% 24.25% 16.45%

Analyst Recommendations

This is a summary of current recommendations for Cadence Pharmaceuticals and Cambrex Corporation, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cadence Pharmaceuticals 0 0 0 0 N/A
Cambrex Corporation 0 0 3 0 3.00

Cambrex Corporation has a consensus price target of $65.67, indicating a potential upside of 17.26%. Given Cambrex Corporation’s higher probable upside, analysts clearly believe Cambrex Corporation is more favorable than Cadence Pharmaceuticals.


Cambrex Corporation beats Cadence Pharmaceuticals on 8 of the 8 factors compared between the two stocks.

Cadence Pharmaceuticals Company Profile

Cadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.

Cambrex Corporation Company Profile

Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc., Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l. Its products consist of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. It delivers services, such as custom organic synthesis and process development; current good manufacturing practices (cGMP) manufacturing of API and intermediates from grams to hundreds of kilograms; cGMP analytical services; controlled substance research and development (R&D) and manufacture, Schedule II-V, and contract research. It has API R&D and cGMP facilities in the United States and Europe. It supplies over 90 generic APIs.

Receive News & Ratings for Cadence Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cadence Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.